Focus: Market Access Policy
Rob is an experienced Director, having worked in pharma strategy consulting, the biotech space, and at NHS England in the national strategy team for the last 10 years. Rob has extensive experience working in pricing and market access strategy projects in US and EU5, including qualitative and quantitative research. He has a strong working knowledge of the US and EU P&R systems, and is familiar with orphan drug pricing dynamics and challenges
